89 related articles for article (PubMed ID: 27391974)
61. Natural compounds regulate energy metabolism by the modulating the activity of lipid-sensing nuclear receptors.
Goto T; Kim YI; Takahashi N; Kawada T
Mol Nutr Food Res; 2013 Jan; 57(1):20-33. PubMed ID: 23180608
[TBL] [Abstract][Full Text] [Related]
62. Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes.
Mashili F; Chibalin AV; Krook A; Zierath JR
Diabetes; 2013 Feb; 62(2):457-65. PubMed ID: 23043161
[TBL] [Abstract][Full Text] [Related]
63. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
[TBL] [Abstract][Full Text] [Related]
64. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.
Dutchak PA; Katafuchi T; Bookout AL; Choi JH; Yu RT; Mangelsdorf DJ; Kliewer SA
Cell; 2012 Feb; 148(3):556-67. PubMed ID: 22304921
[TBL] [Abstract][Full Text] [Related]
65. FGF21 and the second coming of PPARγ.
Qiang L; Accili D
Cell; 2012 Feb; 148(3):397-8. PubMed ID: 22304910
[TBL] [Abstract][Full Text] [Related]
66. Dihydromyricetin as a novel anti-alcohol intoxication medication.
Shen Y; Lindemeyer AK; Gonzalez C; Shao XM; Spigelman I; Olsen RW; Liang J
J Neurosci; 2012 Jan; 32(1):390-401. PubMed ID: 22219299
[TBL] [Abstract][Full Text] [Related]
67. Skeletal muscle mitochondrial capacity and insulin resistance in type 2 diabetes.
Bajpeyi S; Pasarica M; Moro C; Conley K; Jubrias S; Sereda O; Burk DH; Zhang Z; Gupta A; Kjems L; Smith SR
J Clin Endocrinol Metab; 2011 Apr; 96(4):1160-8. PubMed ID: 21307136
[TBL] [Abstract][Full Text] [Related]
68. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
Nissen SE; Wolski K
Arch Intern Med; 2010 Jul; 170(14):1191-1201. PubMed ID: 20656674
[TBL] [Abstract][Full Text] [Related]
69. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway.
Chau MD; Gao J; Yang Q; Wu Z; Gromada J
Proc Natl Acad Sci U S A; 2010 Jul; 107(28):12553-8. PubMed ID: 20616029
[TBL] [Abstract][Full Text] [Related]
70. AMPK activators as novel therapeutics for type 2 diabetes.
Yu LF; Qiu BY; Nan FJ; Li J
Curr Top Med Chem; 2010; 10(4):397-410. PubMed ID: 20180761
[TBL] [Abstract][Full Text] [Related]
71. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.
Trott O; Olson AJ
J Comput Chem; 2010 Jan; 31(2):455-61. PubMed ID: 19499576
[TBL] [Abstract][Full Text] [Related]
72. AMPK: an emerging drug target for diabetes and the metabolic syndrome.
Zhang BB; Zhou G; Li C
Cell Metab; 2009 May; 9(5):407-16. PubMed ID: 19416711
[TBL] [Abstract][Full Text] [Related]
73. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus.
Dostálová I; Haluzíková D; Haluzík M
Physiol Res; 2009; 58(1):1-7. PubMed ID: 19331512
[TBL] [Abstract][Full Text] [Related]
74. FGF21 is an Akt-regulated myokine.
Izumiya Y; Bina HA; Ouchi N; Akasaki Y; Kharitonenkov A; Walsh K
FEBS Lett; 2008 Nov; 582(27):3805-10. PubMed ID: 18948104
[TBL] [Abstract][Full Text] [Related]
75. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states.
Muise ES; Azzolina B; Kuo DW; El-Sherbeini M; Tan Y; Yuan X; Mu J; Thompson JR; Berger JP; Wong KK
Mol Pharmacol; 2008 Aug; 74(2):403-12. PubMed ID: 18467542
[TBL] [Abstract][Full Text] [Related]
76. Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes.
Wang H; Qiang L; Farmer SR
Mol Cell Biol; 2008 Jan; 28(1):188-200. PubMed ID: 17954559
[TBL] [Abstract][Full Text] [Related]
77. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.
Rathmann W; Giani G
Diabetes Care; 2004 Oct; 27(10):2568-9; author reply 2569. PubMed ID: 15451946
[No Abstract] [Full Text] [Related]
78. Ampelopsin Improves Insulin Resistance by Activating PPARγ and Subsequently Up-Regulating FGF21-AMPK Signaling Pathway.
Zhou Y; Wu Y; Qin Y; Liu L; Wan J; Zou L; Zhang Q; Zhu J; Mi M
PLoS One; 2016; 11(7):e0159191. PubMed ID: 27391974
[TBL] [Abstract][Full Text] [Related]
79. FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process.
Salminen A; Kauppinen A; Kaarniranta K
J Mol Med (Berl); 2017 Feb; 95(2):123-131. PubMed ID: 27678528
[TBL] [Abstract][Full Text] [Related]
80. Fibroblast growth factor 21 - a key player in cardiovascular disorders?
Lenart-Lipińska M; Duma D; Hałabiś M; Dziedzic M; Solski J
Horm Mol Biol Clin Investig; 2016 Jun; 30(2):. PubMed ID: 27305706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
